Skip to content

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Learn more

.

Actinium-225

Explore the potential of Actinium-225, a synthetic isotope with a crucial role in Targeted Alpha Therapy for cancer treatment.

Actineer Inc. is a new joint venture for industrial scale production of Actinium-225

Actineer Inc. was founded in 2023 by ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian Nuclear Laboratories (CNL), which manages and operates the national laboratory at Chalk River, Ontario, on behalf of Atomic Energy of Canada Limited (AECL).

As a rare alpha emitting medical isotope, Ac-225 is gaining increasing attention across the precision oncology field due to its significant potential as a powerful new potential weapon in the fight against cancer.

Plenty of radiopharmaceutical companies included Ac-225-based molecules as lead program to their pipeline already being well advanced in some cases and requiring this radioisotope as starting material on-time in-full.

The joint venture’s overall goal is to fulfill the unmet global needs of Actinium-225 in order to ensure a reliable supply urgently needed for next generation radiopharmaceuticals and patients worldwide.

.

Latest News

December 7th, 2023

Actinium-225 production

Toronto – December 7 2023 – In support of Canadian Nuclear Isotope Council’s (CNIC) goal of ensuring a reliable supply of medical...

Learn more
October 18th, 2023

ITM and CNL Announce the Launch of Actineer

ITM Isotope Technologies Munich SE (ITM), a leading radio- pharmaceutical biotech company, and Canadian Nuclear Laboratories (CNL)

Learn more

Mission

We strive everyday to produce and deliver the highest quality radioisotopes, to be a reliable and robust partner so that everyone who needs our highest specification medical isotopes can access the care that they need.

.

Actineer Quotes

.

Our joint venture Actineer has been launched with the overall goal to ensure access to Ac-225 as a next generation radioisotope through an innovative technology.
With the foundation of Actineer we have committed us to establish a reliable, long term and substantial production of Ac-225 in high quality standards.
This Canada based company will facilitate ground breaking research activities leading to novel cancer treatments urgently needed by many patients worldwide.

Andreas Benischke, COO of Actineer
.

Two companies with long and distinguished histories of delivering medical isotopes to the global market have come together to help realize the potential that Ac-225-based radiopharmaceuticals’ promise. CNL has been fostering the Ac-225 market for years. The creation of the joint venture with ITM will accelerate advancing the technology needed to produce large quantities.

Ram Mullur, President of Actineer
.

It is our role to drive nuclear innovation in Canada, to bring private and public expertise together to spark these new initiatives that will ultimately benefit the health of Canadians and bring new jobs to Canada. We are building on decades of Canada’s world-leading isotope innovation, and have found the key to success is collaboration, partnership, and strong leadership. We are pleased to support the joint venture between CNL and ITM with shared values to bring this potentially lifesaving therapy to the world.

Fred Dermarkar, President and 
CEO of AECL
.

Together with ITM, CNL has already made significant process towards our goal of bringing a next-generation medical isotope to the world market. With the launch of Actineer, we are poised to establish a reliable and large-scale supply of Ac-225 that we believe will unlock ground-breaking new cancer treatments. The entire team at CNL looks forward to applying their radiochemical expertise to the development of the new production process for Actinium-225 within this joint venture.

Joe McBrearty, CNL’s President and CEO
.

Targeted alpha therapies based on Actinium-225 are gaining increasing importance in addition to the well-established beta emitters such as our highly-pure non-carrier-added (n.c.a.) Lutetium-177. Joining forces with CNL provides us the opportunity to extend our therapeutic portfolio as we continue striving to meet the needs of healthcare professionals and cancer patients worldwide.

Steffen Schuster, ITM CEO

Current Partnerships

ITM
SFCCNI
CNL
CNIC
USask
ACSI